financetom
Business
financetom
/
Business
/
Allahabad Bank divests its CEO Usha Ananthasubramanian of all powers
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Allahabad Bank divests its CEO Usha Ananthasubramanian of all powers
May 15, 2018 1:11 PM

The Board of state-owned Allahabad Bank on Tuesday divested its MD and CEO Usha Ananthasubramanian of all powers with immediate effect, following a directive from the finance ministry after she was named in the CBI's chargesheet in Punjab National Bank (PNB) fraud case.

"...the Board of Directors of the Bank in its meeting held on date has decided that Smt Usha Ananthasubramanian, MD & CEO be divested of all functional responsibilities of the Bank with immediate effect...," Allahabad Bank said in a regulatory filing.

Ananthasubramanian, was the CMD of PNB till May 2017.

It further asked the government to make suitable arrangements for smooth functioning of the bank.

Earlier on Monday, the finance ministry had asked the boards of Allahabad Bank and PNB to take action against Ananthasubramanian and two executive directors of PNB.

On Monday, the PNB had divested its two executive directors of all powers.

The CBI on Monday filed its first chargesheet in the PNB fraud case detailing the roles of Nirav Modi, his brother Nishal Modi and Subhash Parab, an executive in Nirav Modi's company.

Meanwhile, PNB on Tuesday said that its total liability works out to Rs 14,356.84 crore on account of the fraud allegedly carried out by jewellery designer Nirav Modi and associates.

The fraud was detected at PNB's Brady House branch in Mumbai involving certain accounts under 'gems and jewellery' sector wherein, through apparent connivance between "these entities and few employees of the bank", some LoUs/FLCs were issued fraudulently to certain overseas branches of Indian banks through misuse of the SWIFT messaging system.

First Published:May 15, 2018 10:11 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
KKR Goes Surgical: Snags Indian Medical Devices Company Healthium From Apax
KKR Goes Surgical: Snags Indian Medical Devices Company Healthium From Apax
May 6, 2024
KKR & Co. Inc. ( KKR )  announced the signing of definitive agreements to acquire Healthium Medtech Ltd. from an affiliate of Funds advised by Apax Partners LLP. Financial details were not disclosed. Based in India, Healthium is a medical devices company that develops, manufactures, and sells a broad range of surgical products worldwide. Akshay Tanna, Partner and Head of India Private Equity at KKR, said: “Under the...
Spirit Airlines forecasts weak Q2 revenue on slow growth in domestic demand
Spirit Airlines forecasts weak Q2 revenue on slow growth in domestic demand
May 6, 2024
May 6 (Reuters) - Spirit Airlines ( SAVE ) forecast weak second-quarter revenue on Monday due to sluggish improvement in domestic demand and grounding of dozens of its aircraft. The airline is among the most heavily impacted by issues with RTX's Pratt & Whitney Geared Turbofan engines, which have forced it to ground multiple aircraft and resulted in high labor...
BRIEF-Allete Enters Agreement To Be Acquired By A Partnership Led By Canada Pension Plan Investment Board And Global Infrastructure Partners To Advance 'Sustainability-In-Action' Strategy
BRIEF-Allete Enters Agreement To Be Acquired By A Partnership Led By Canada Pension Plan Investment Board And Global Infrastructure Partners To Advance 'Sustainability-In-Action' Strategy
May 6, 2024
May 6 (Reuters) - ALLETE Inc ( ALE ): * ALLETE ENTERS AGREEMENT TO BE ACQUIRED BY A PARTNERSHIP LED BY CANADA PENSION PLAN INVESTMENT BOARD AND GLOBAL INFRASTRUCTURE PARTNERS TO ADVANCE 'SUSTAINABILITY-IN-ACTION' STRATEGY * ALLETE INC ( ALE ): SHAREHOLDERS TO RECEIVE $67.00 PER SHARE IN CASH * ALLETE INC ( ALE ): PROPOSED DEAL FOR $6.2 BILLION *...
Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib
Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib
May 6, 2024
07:43 AM EDT, 05/06/2024 (MT Newswires) -- Redhill Biopharma ( RDHL ) said Monday it was awarded a new patent in China for investigational drug opaganib as a therapy to inhibit single-stranded RNA virus replication, notably Ebola virus disease. The patent, issued by the Chinese National Intellectual Property Administration, is valid through 2035, according to Redhill. The company said opaganib...
Copyright 2023-2025 - www.financetom.com All Rights Reserved